{"id":511318,"date":"2021-07-09T08:03:14","date_gmt":"2021-07-09T12:03:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\/"},"modified":"2021-07-09T08:03:14","modified_gmt":"2021-07-09T12:03:14","slug":"reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\/","title":{"rendered":"Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, July  09, 2021  (GLOBE NEWSWIRE) &#8212; Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, announced today that Jefferies LLC, SVB Leerink LLC and Piper Sandler, as the representatives of the several underwriters of Reneo\u2019s initial public offering, have agreed to waive the lock-up restriction with respect to 111,736 shares of common stock held by Wendy Johnson, an officer of the company who previously announced her intention to retire on or before December 31, 2021. The waiver for Ms. Johnson will take effect on July 13, 2021 and the shares may be sold on or after such date.\u00a0\u00a0<\/p>\n<p>\n        <strong>This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended.<\/strong>\n      <\/p>\n<p>\n        <strong>About Reneo Pharmaceuticals<\/strong><br \/>\n        <br \/>Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.<\/p>\n<p>Contacts:<\/p>\n<p>Joyce Allaire<br \/><em>Managing Director<\/em><br \/>LifeSci Advisors, LLC<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Wai3BLQDiyVssNBirS6i4TqE1OblmzLydzC6-80fr3DxDjNZG_k_xOR-1SfUZvwN9Dc-G1a8wl31Zsd7omHViAHyWJEpypzFyizKmiltCL-QbcJXB_EwOfdHkYXP0BLm\" rel=\"nofollow noopener\" target=\"_blank\">jallaire@lifesciadvisors.com<\/a><\/p>\n<p>Vinny Jindal<br \/><em>Chief Financial Officer<\/em><br \/>Reneo Pharmaceuticals, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w1Y-SDthicNUhvBxGP0fnzRz1QQebPF2yuTIWoq3FGyKjINs2tbxWdPMAUxw0Uf02WTKfY4UUXyLNQSKVGcnBbCUBnFgiJyaQ47sEfOq9CA=\" rel=\"nofollow noopener\" target=\"_blank\">investors@reneopharma.com<\/a><\/p>\n<p>\n        \n      <\/p>\n<p \/>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzkwNCM0MjkwMDkzIzIyMDcyMTA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/d799aef7-e27e-4f17-baa0-942da61df0b9\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, July 09, 2021 (GLOBE NEWSWIRE) &#8212; Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, announced today that Jefferies LLC, SVB Leerink LLC and Piper Sandler, as the representatives of the several underwriters of Reneo\u2019s initial public offering, have agreed to waive the lock-up restriction with respect to 111,736 shares of common stock held by Wendy Johnson, an officer of the company who previously announced her intention to retire on or before December 31, 2021. The waiver for Ms. Johnson will take effect on July 13, 2021 and the shares may be sold on or after such date.\u00a0\u00a0 This press release is &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-511318","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, July 09, 2021 (GLOBE NEWSWIRE) &#8212; Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, announced today that Jefferies LLC, SVB Leerink LLC and Piper Sandler, as the representatives of the several underwriters of Reneo\u2019s initial public offering, have agreed to waive the lock-up restriction with respect to 111,736 shares of common stock held by Wendy Johnson, an officer of the company who previously announced her intention to retire on or before December 31, 2021. The waiver for Ms. Johnson will take effect on July 13, 2021 and the shares may be sold on or after such date.\u00a0\u00a0 This press release is &hellip; Continue reading &quot;Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-09T12:03:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzkwNCM0MjkwMDkzIzIyMDcyMTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction\",\"datePublished\":\"2021-07-09T12:03:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\\\/\"},\"wordCount\":283,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NzkwNCM0MjkwMDkzIzIyMDcyMTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\\\/\",\"name\":\"Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NzkwNCM0MjkwMDkzIzIyMDcyMTA=\",\"datePublished\":\"2021-07-09T12:03:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NzkwNCM0MjkwMDkzIzIyMDcyMTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NzkwNCM0MjkwMDkzIzIyMDcyMTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\/","og_locale":"en_US","og_type":"article","og_title":"Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction - Market Newsdesk","og_description":"SAN DIEGO, July 09, 2021 (GLOBE NEWSWIRE) &#8212; Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, announced today that Jefferies LLC, SVB Leerink LLC and Piper Sandler, as the representatives of the several underwriters of Reneo\u2019s initial public offering, have agreed to waive the lock-up restriction with respect to 111,736 shares of common stock held by Wendy Johnson, an officer of the company who previously announced her intention to retire on or before December 31, 2021. The waiver for Ms. Johnson will take effect on July 13, 2021 and the shares may be sold on or after such date.\u00a0\u00a0 This press release is &hellip; Continue reading \"Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-09T12:03:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzkwNCM0MjkwMDkzIzIyMDcyMTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction","datePublished":"2021-07-09T12:03:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\/"},"wordCount":283,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzkwNCM0MjkwMDkzIzIyMDcyMTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\/","name":"Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzkwNCM0MjkwMDkzIzIyMDcyMTA=","datePublished":"2021-07-09T12:03:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzkwNCM0MjkwMDkzIzIyMDcyMTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzkwNCM0MjkwMDkzIzIyMDcyMTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/511318","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=511318"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/511318\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=511318"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=511318"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=511318"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}